arrow_back Back to App

Ending Hidden Fees from Pharmacy Benefit Managers

This act aims to lower prescription drug costs for citizens. It prohibits Pharmacy Benefit Managers (PBMs) from collecting hidden fees from health plans. Instead, PBMs will only be allowed to charge transparent, flat fees for their services, which should increase transparency and potentially reduce drug prices.
Key points
Starting January 1, 2027, Pharmacy Benefit Managers (PBMs) will be prohibited from collecting hidden fees or commissions from health plans that are tied to drug prices.
PBMs will only be allowed to charge transparent, flat fees for their services, which will not depend on drug prices or rebates obtained.
Violations of these rules will result in significant financial penalties ($10,000 per day) and the obligation to return unfairly collected money to health plans.
The goal is to increase transparency in the pharmaceutical industry and potentially lower prescription drug costs for patients.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_2214
Sponsor: Rep. Miller-Meeks, Mariannette [R-IA-1]
Process start date: 2025-03-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

DRUG Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_2214.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-03-18.

What are the main provisions?

Key points include:

  • Starting January 1, 2027, Pharmacy Benefit Managers (PBMs) will be prohibited from collecting hidden fees or commissions from health plans that are tied to drug prices.
  • PBMs will only be allowed to charge transparent, flat fees for their services, which will not depend on drug prices or rebates obtained.
  • Violations of these rules will result in significant financial penalties ($10,000 per day) and the obligation to return unfairly collected money to health plans.
  • The goal is to increase transparency in the pharmaceutical industry and potentially lower prescription drug costs for patients.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller-Meeks, Mariannette [R-IA-1].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Economy